Serum microRNA profiles as prognostic biomarkers for HBVpositive hepatocellular carcinoma

28Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

To establish serum microRNA profiles as prognostic biomarkers in hepatocellular carcinoma patients (HCCs), we used deep sequencing to screen serum microRNAs in a discovery set .Twelve up-regulated serum miRNAs were selected for qPCR analysis in a training set. MiR-192-5p and miR-29a-3p were identified and associated with HCC prognosis. HCCs with high concentrations of miR-192-5p and miR-29a-3p had poorer overall survival (OS) and progression-free survival (PFS) than those with low concentrations. We calculated a prognostic index (PI) score and classified patients into low-, medium- and high-risk groups. OS and PFS among the 3 groups from the training set were significantly different (all P < 0.05). PI (PIOS, PIPFS) score was the only independent prognostic predictor for OS and PFS of HCCs in the training set. These results were further confirmed in a validation set. In conclusion, differentially expressed serum miRNAs can be helpful for predicting survival in HCCs.

Cite

CITATION STYLE

APA

Zhu, H. T., Hasan, A. M. E., Liu, R. B., Zhang, Z. C., Zhang, X., Wang, J., … Shao, J. Y. (2016). Serum microRNA profiles as prognostic biomarkers for HBVpositive hepatocellular carcinoma. Oncotarget, 7(29), 45637–45648. https://doi.org/10.18632/oncotarget.10082

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free